Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

Author： Markman M.   Blessing J.A.   Alvarez R.D.   Hanjani P.   Waggoner S.   Hall K.  

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.77, Iss.1, 2000-04, pp. : 112-115

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Bookman M.A.   Creasman W.T.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 32-35

Elsevier

Access to resources Recommend Favorite

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Nunez E.R.  

Gynecologic Oncology, Vol. 81, Iss. 3, 2001-06 ,pp. : 433-435

Elsevier

Access to resources Recommend Favorite

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A.   Blessing J.A.   Hurteau J.A.  

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite

Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial

By Markman M.   Blessing J.A.   DeGeest K.   Morgan M.   Look K.Y.   Herzog T.J.   Rose P.G.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 444-446

Elsevier

Access to resources Recommend Favorite

Phase II Trial of CI-958 in Recurrent Platinum-Refractory Ovarian Carcinoma - A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Morgan M.  

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 463-465

Elsevier

Access to resources Recommend Favorite